RANBP3 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, it is well known that the kinase activity of BCR-ABL in CML can activate the downstream MAPK and AKT pathways (7), and RanBP3 has been reported to be the common downstream of the two pathways (26).